BRISBANE, Queensland, May 29 -- Queensland Health issued the following media release:
The community is invited to contribute to an independent review of the prescribing of puberty blockers and gender-affirming therapies in Queensland's public paediatric gender services.
The review, led by Professor Ruth Vine, is examining the evidence and ethical considerations surrounding the use of puberty suppression (Stage 1) and gender affirming (Stage 2) hormone therapies to treat children with gender dysphoria in the public health system.
Public consultation through written submissions begins on 29 May 2025 and will close on 29 July 2025.
The review panel will also approach key stakeholders including public and private clinicians, professional co...